Sunday, March 08, 2009

Stem Cell Stocks Update

On Monday, President Barack Obama will be signing an executive order to eliminate a ban on federal funding for embryonic stem-cell research. This major change in policy will cause the research into stem cell therapy to increase substantially. Research has been continuing to utilize stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions.

Stem cells can come from embryos and from cord blood, the blood from umbilical cords, and even in baby teeth.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with a $2.6 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The stock has a forward PE of 83.

ARIAD Pharmaceuticals (ARIA) is a Massachusetts based company, with a $83 million market cap, that is involved in the development of treatments for cancer by using small molecules to regulate cell signaling. Their cancer products are used to treat solid tumors, sarcomas, hormone refractory prostate cancer, and endometrial cancer. The stock has generated negative earnings. It is an extremely low cap stock and should be considered extremely speculative.

Celera Group (CRA) is a company that was founded in 1937. They have a market cap of $450 million. It is involved in the research of new diagnostic markers, using proprietary genomics and proteomics discovery procedures and diagnostic products. Some of their products are used for the detection of HIV, hepatitis C, and cystic fibrosis. They are in collaboration with Abbott Laboratories (ABT), Genentech (DNA), and General Electric (GE). The stock has generated negative earnings.

Cellgene (CELG) is a $18.9 billion market cap company involved in the discovery and production, of therapies designed to treat cancer and immune-inflammatory-related diseases. One of their main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received patent on placental stem cell recovery. The stock has recently generated negative earnings.

Cytori Therapeutics, Inc. (CYTX) is a $68 million market cap company that makes and markets regenerative medicine medical technologies. They have recently generated negative earnings. This is an extremely low cap stock and should be considered extremely speculative.

Dendreon Corporation (DNDN) This $253 million market cap company is involved in the discovery, development, and sales of active immunotherapies, monoclonal antibodies, and small molecule product candidates to treat cancer. They also manufacture the DACSĂ’SC stem cell enrichment device. The stock has had negative earnings.

Geron (GERN) is a Menlo Park, California based $307 million market cap company which develops cell-based therapies derived from human embryonic stem cells used for the treatment of various diseases and medical conditions such as spinal cord damage, heart failure, and diabetes. They have the first federally approved human study utilizing embryonic stem cell therapy. The stock has had negative earnings.

Integra Lifesciences Holdings (IART) is a New Jersey based $571 million market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. Their P/E is 37, and the PEG is 0.68.

Invitrogen Corporation (LIFE) is a California based $4.9 billion market cap company which sells products and services to research institutions, pharmaceutical companies and biotechnology companies, including tools for gene acquisition, gene cloning, and gene analysis techniques. The stock has a P/E of 93.

Neuralstem Inc. (CUR) is a $27 million market cap company that develops and markets human neural stem cell technology. They have recently generated negative earnings. This is an extremely low cap stock and should be considered extremely speculative.

Osiris Therapeutics, Inc. (OSIR) is a $588 million market cap company, which markets stem cell products from adult bone marrow. They have recently generated negative earnings.

StemCells Inc. (STEM) is a $112 market cap company involved in the development, and marketing of cell-based therapeutics to treat liver diseases and diseases of the central nervous system. They have recently generated negative earnings. This is a low cap stock and should be considered very speculative.

For an Excel database of stem cell stocks which you can download, sort, and change, go to WallStreetNewsNetwork.com.

Also, check out gene therapy stocks and cord blood stocks.

Author does not own any of the above.

By Stockerblog.com

3 comments:

phyl said...

As we age, the number and quality of stem cells that circulate in our body gradually decrease, leaving our body more susceptible to injury and other age-related health challenges. StemTech Health Science's Stem Enhance is the alternative to the controversial stem cells we hear about in the news. Patented Product StemEnhance supports the natural release of stem cells to promote optimal healing and stem cell physiology.

Officials at StemTech Health Sciences were aiming for Stem Enhance sales of $100,000 in the first month. Which was a hearty goal in itself. Imagine their astonishment when the 1st month's sales totaled over $1,000,000 and it just keeps rising.http://www.phyl247.biz office 970-985-4076

Sujan Patricia said...

There is no ban on embryonic stem cell research for President Obama to lift. When Bush provided federal funding for embryonic stem cell research, which no President had done before him, he restricted what research that funding could be used for. He did not ban embryonic stem cell research.

Thanks,
Patricia
my site

Jane Kellogg said...

Look at SCLL.PK They make money in the Liver Stem Cell Cancer market. Their volume has gone up 300%

I think they have got something and they are quietly buying up all their stock before they announce and explode